Evidence map›Paper›PMID 25544581›Full record

ArticleCancer research and treatment2015

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.

Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Burkitt lymphoma in adolescents and young adults: management challenges.Adolescent health, medicine and therapeutics · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Junshik HongDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Seok Jin KimDepartment of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Korea.
Jae-Sook AhnDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Moo Kon SongDepartment of Hematology-Oncology, Pusan National University Hospital, Busan, Korea.
Yu Ri KimDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ho Sup LeeDepartment of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Ho-Young YhimDepartment of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Min Kyoung KimDepartment of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University Hospital, Busan, Korea.
Yong ParkDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Yeung-Chul MunDepartment of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.
Young Rok DoDepartment of Hematology-Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Hun-Mo RyooDepartment of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
Je-Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Jae Hoon LeeDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Won Seog KimDepartment of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, Korea.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). MATERIALS AND

methodsPatients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.

resultsForty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.

conclusionR-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Indexed as

Burkitt lymphomaCVAD protocolRituximab

Identifiers

PMID25544581
PMCPMC4398112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.